Prof Belinda Parker
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
103 Scholarly works
31 Projects
HIGHLIGHTS
2026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
DOI: 10.1038/s41467-026-74334-z2026
Journal article
Striking the right balance with type I interferon signalling in cancer
DOI: 10.1038/s41568-026-00915-12026
Journal article
Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling.
DOI: 10.1186/s13058-026-02296-72025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52023
Research grants (ARC, NHMRC, MRFF)
Targeting Crosstalk in the Tumour Microenvironment for Precision Cancer Therapy
2023
Research grants (other domestic)
Targeting the Hormone-Immune Cell Axis to Prevent Breast Cancer Progression
2019
Research Grant
PRECEPT - PRostatE CancEr Prognosis and Treatment
RECENT SCHOLARLY WORKS
2025
Journal article
Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance
DOI: 10.1158/2326-6074.cimm25-pr-022025
Conference Proceedings
2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
DOI: 10.1016/j.annonc.2025.08.30022025
Journal article
Abstract P5-10-30: Developing microenvironment-based prognostic biomarkers for early breast cancer
DOI: 10.1158/1557-3265.sabcs24-p5-10-302025
Journal article
Abstract P5-08-08: Predicting local recurrence in DCIS treated predominantly without radiation
DOI: 10.1158/1557-3265.sabcs24-p5-08-082024
Journal article
The complexity of immune evasion mechanisms throughout the metastatic cascade
DOI: 10.1038/s41590-024-01960-42023
Journal article
Interferon-ε is a tumour suppressor and restricts ovarian cancer
DOI: 10.1038/s41586-023-06421-w
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Unraveling Metastasis-Specific Immune Niches to Transform Cancer Treatment
2025
Research grants (other domestic)
Testing Alternate Therapeutic Strategies for Bone Metastatic Prostate Cancer